

VPH Institute

Building the Virtual Physiological Human



CONTRIBUTE TO MAKE IN SILICO MEDICINE A REALITY!

The Avicenna Alliance (AA) is a global association of organisations, having a commercial or research interest in the development, adoption and deployment of in silico medicine to ensure safe, affordable and cost-efficient healthcare.

The AA academic membership is represented by the VPH Institute. Thanks to this strategic asset, the VPH Institute can offer all its members the opportunity to access and contribute to all the Avicenna Alliance's activities.

Collaboration among AA members takes place through the participation of different working groups, where members share their knowledge and expertise, writing white papers, publishing case studies, organising events and establishing collaborations with regulators and policy makers all over the world.

Get an overview of the 4 working groups and related task forces of the Avicenna Alliance!

POLICY DEVELOPMENT WORKING GROUP



Martha De Cunha Maluf-Burgman, MBA

Director Regulatory Affairs Digital Health, Edwards Lifesciences

To build a forward-looking policy framework to facilitate the large scale deployment of in silico technology and their acceptance by health authorities.

TASK FORCES

■ **Pharmaceutical Strategy**

Inform and guide global Competent Authorities and propose concrete avenues, and texts, to engage Europe, US and other regions in the Digitalisation of the Regulatory Pharmaceutical activities.

Co-Chairs: *Cécile De Coste (Alexion), Shiny Martis (Nova Discovery)*

■ **European Medicine Agency (EMA) Collaboration**

Closely collaborate with EMA to inform them about the progress of in silico methods and learn about EMA requirements to accept digital evidence.

Co-Chairs: *Liesbet Geris (VPHI, U.Liège, KU Leuven), Martha De Cunha Maluf-Burgman (Edwards Lifesciences)*

■ **Good Simulation Practice**

Drafting a Good Simulation Practice document widely recognized and accepted similar to the Good Clinical Practice.

Co-Chairs: *Luca Emili (InSilicoTrials), Marco Viceconti (University of Bologna)*

■ **Public & Patient Involvement (PPI)**

Empower the public & patients to understand the potential of in silico medicine, improve healthcare creating 'user demand', encourage greater funding and drive broader clinical and regulatory adoption for enhanced impact.

Co-Chairs: *Cyrille Thinnes (NUI Galway), Steve Levine (Dassault Systèmes)*

■ **Notified Bodies**

Engage with NBs to increase acceptance of in silico evidence in Europe, provide NBs with guidance documents and offer them assistance in the review process of digital evidence.

Co-Chairs: *Simon Sonntag (Virtonomy), Bernard Staumont (University of Liège)*

RESEARCH & TECHNOLOGY WORKING GROUP



Liesbet Geris

Executive Director, VPH Institute

Professor, University of Liège & KU Leuven (Belgium)

Bridge the missing mile between basic research and the commercialization of products and provide a unique opportunity to explore areas of mutual cooperation and benefit & cost for treatment approval and reimbursement

TASK FORCES

■ **Cancer & In Silico Oncology Task force**

Accelerate, optimize and personalize cancer treatment through the development, clinical validation and clinical translation of in silico methods.

Co-Chairs: Georgios Stamatakos (National Technical University of Athens), Ángel Alberich-Bayarri (Quibim)

■ **Tissue Characterization**

Create a data base of biological tissue properties with Certificate of Birth.

Co-Chairs: V Nele Famaey (KU Leuven), Venkat Perumal (Stryker)

■ **Artificial Intelligence**

Engage in all AA activities related to AI.

Co-Chairs: Jérôme Noailly (*Universitat Pompeu Fabra*), Gordon Johnston (*Johnson & Johnson*)

■ **Horizon Europe**

Monitor, influence & inform on Horizon Europe Funding.

Chair: Liesbet Geris (*VPHi, U.Liège, KU Leuven*)

INTERNATIONAL WORKING GROUP

Nathalie Virag, PhD

*Distinguished Scientist & Bakken Fellow, Corporate Technology
and Innovation, Medtronic*



To facilitate dialogue on in silico with regulators and stakeholders around the world; to support harmonization and regulatory reliance policies for in silico methods and in silico clinical trials and to seek opportunities to expand the Alliance geographically.

TASK FORCES

■ Global Harmonization

Inform and educate regulatory agencies around the world to ensure harmonized adoption of in silico methods.

Chair: Marc Horner (*Ansys*)

■ UK In Silico Regulatory Innovation

Nurture a cross-sector UK in silico trials community for regulatory science & innovation to produce evidence and harmonize standards in the UK accelerating in silico adoption in regulations.

Co-Chairs: Alex Frangi (*University of Leeds*), David Flynn (*Boston Scientific*)

IN SILICO APPLICATION WORKING GROUP



Cécile Rousseau

Senior Director Nonclinical, Voising Consulting Life Sciences



Emmanuelle Voisin

Founder & CEO, Voisin Consulting Life Sciences

Deploy in silico methods downstream and design comprehensive solutions (process, access to research, software, hardware, humanware, possibly services) to allow any organization to time and cost effectively adopt and deploy in silico methods all along the development, registration and life cycle of the products.

TASK FORCES

■ IN SILICO LIABILITIES

Accelerate, optimize and personalize cancer treatment through the development, clinical validation and clinical translation of in silico methods

Chair: Thierry Marchal (Ansys)

All VPHi members can contribute to these important activities. If you want to get involved, contact manager@vph-institute.org

vph-institute.org
avicenna-alliance.com



Avicenna Alliance
Association for Predictive Medicine